Previous close | 2.4000 |
Open | 2.4800 |
Bid | 2.3800 x 500 |
Ask | 2.4300 x 400 |
Day's range | 2.3900 - 2.5300 |
52-week range | 2.3800 - 5.5600 |
Volume | |
Avg. volume | 112,356 |
Market cap | 104.666M |
Beta (5Y monthly) | 1.29 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
New products complement an already extensive range of products enabling fundamental advancements in neuroscience researchHOLLISTON, Mass., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that it will be showcasing its latest product innovations at the Society for Neuroscience (SfN) 2024 Annual Meeting being held October 5 - 9 in Chicago. Cutting-edge innovations on display include the revolutionary new Mesh MEA™ microelectrode array system, the SoHo™ imp
Solutions for CROs, pharma and biotechs streamline testing and enable fundamental advancements in preclinical and organoid focused therapy developmentHOLLISTON, Mass., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that it will be showcasing its latest product innovations at the Safety Pharmacology Society (SPS) Annual Meeting being held from September 22-25, 2024, in San Diego. DSI™ Ponemah™ Data Management Platform Provides Integrated Preclinical Sol
HOLLISTON, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Jim Green, Chairman and Chief Executive Officer, and Jennifer Cote, Chief Financial Officer, will be participating in the Sidoti Small Cap Virtual Conference on September 18th, 2024, with a presentation time of 9:15 am ET. The presentation will be webcast live and can be accessed through the investor relations section of the Harvard Bioscience website: https://investor.harvardbioscie